The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Chemo-free regimens continue for CLL
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the current landscape of chemotherapy-free regimens for chronic lymphocytic leukemia (CLL). The introduction of more targeted oral agents, such as ibrutinib and venetoclax, has led to these agents being tested in upfront studies compared to chemoimmunotherapy. Several large randomized trials doing just this were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
